Jacobio’s New Cancer Drug Enters Clinical Trials

Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.

Jacobio Pharmaceuticals has announced that China’s CDE has approved their Investigational New Drug application for JAB-23E73, a Pan-KRAS inhibitor aimed at treating various tumor mutations. The drug, which has already had its IND application approved by the U.S. FDA, is poised to enter phase I/IIa clinical trials for advanced solid tumor patients in China and the U.S. This development could potentially benefit the yearly 2.7 million new patients with KRAS-related mutations.

For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.